secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2021-12-23T23:59:59+00:00
Accession:  0001654954-21-013517
Event type: regulatory
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma regains Nasdaq compliance for independent director and audit committee rules
--------------------------------------------------------------------------------

- Received Nasdaq Staff letter on Dec 22, 2021 confirming compliance with Listing Rule 5605(b)(1).
- Prior non-compliance stemmed from Michael Breen's appointment as Executive Chairman on Nov 8, 2021.
- Nasdaq had notified the company of the deficiency on Nov 23, 2021.
- Compliance restored following resignation of director Anthony Cataldo effective Dec 15, 2021; matter closed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000165495421013517/0001654954-21-013517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000165495421013517/gtbp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-21-013517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer